Geron Corporation (NASDAQ:GERN) Receives $2.75 Average Target Price from Brokerages

Shares of Geron Corporation (NASDAQ:GERN) have been assigned a consensus rating of “Hold” from the ten research firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $2.75.

Several analysts have issued reports on the stock. Needham & Company LLC lowered their target price on shares of Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Geron in a research report on Wednesday, January 28th. UBS Group restated a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. HC Wainwright restated a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th. Finally, TD Cowen reiterated a “buy” rating on shares of Geron in a research report on Thursday, January 29th.

Geron Stock Down 2.6%

Shares of NASDAQ GERN opened at $1.47 on Friday. The company has a quick ratio of 4.87, a current ratio of 5.96 and a debt-to-equity ratio of 0.48. The company has a market cap of $938.37 million, a P/E ratio of -12.25 and a beta of 0.62. Geron has a 52 week low of $1.04 and a 52 week high of $3.09. The business has a 50-day simple moving average of $1.34 and a two-hundred day simple moving average of $1.30.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). Geron had a negative net margin of 43.61% and a negative return on equity of 29.63%. The firm had revenue of $47.23 million for the quarter, compared to the consensus estimate of $55.24 million. Research analysts anticipate that Geron will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Geron

Institutional investors have recently made changes to their positions in the stock. 55 North Private Wealth LLC bought a new stake in shares of Geron during the 4th quarter worth $29,000. LCM Capital Management Inc lifted its stake in Geron by 80.6% during the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 10,000 shares during the last quarter. Swiss Life Asset Management Ltd boosted its holdings in shares of Geron by 73.6% in the 3rd quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 11,182 shares in the last quarter. Savant Capital LLC boosted its holdings in shares of Geron by 73.8% in the 2nd quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 11,074 shares in the last quarter. Finally, Fisher Asset Management LLC bought a new position in shares of Geron during the 3rd quarter valued at about $37,000. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.